![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Intchains Group
ICG
BIGG DIGITAL ASSETS INC
BBKCF
NEPTUNE DIGITAL ASSETS CORP
NPPTF
Bitdeer Technologies
BTDR
FRMO CORP
FRMO
US Stock MarketDetailed Quotes
IVVD Invivyd
- 0.444
- +0.014+3.30%
Close Dec 20 16:00 ET
- 0.430
- -0.014-3.11%
Post 20:01 ET
53.10MMarket Cap-0.23P/E (TTM)
0.453High0.404Low2.34MVolume0.420Open0.430Pre Close1.00MTurnover4.99%Turnover RatioLossP/E (Static)119.62MShares5.19552wk High0.64P/B20.76MFloat Cap0.40452wk Low--Dividend TTM46.77MShs Float78.820Historical High--Div YieldTTM11.29%Amplitude0.404Historical Low0.430Avg Price1Lot Size
Invivyd Stock Forum
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
26
7
7
$Invivyd (IVVD.US)$
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter...
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter...
1
$Invivyd (IVVD.US)$ Benzinga· 3 mins ago
Invivyd Publishes CANOPY Phase 3 Trial Data Preprints Showing Long-Term COVID-19 Protection By Pemivibart Against JN.1 Sublineages; Novel Method For Predicting Monoclonal Antibody Activity Against Emerging Variants Detailed In BioRxiv
Invivyd Publishes CANOPY Phase 3 Trial Data Preprints Showing Long-Term COVID-19 Protection By Pemivibart Against JN.1 Sublineages; Novel Method For Predicting Monoclonal Antibody Activity Against Emerging Variants Detailed In BioRxiv
$Invivyd (IVVD.US)$ Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (Pemivibart) Provided Substantial Protection From Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
GlobeNewswire· 12 mins ago
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...
GlobeNewswire· 12 mins ago
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...
2
$Invivyd (IVVD.US)$
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutral...
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutral...
1
$Invivyd (IVVD.US)$ i support this stock
New targets for next week:
$Invivyd (IVVD.US)$ - makes COVID antibodies, w/ a phase 3 trial completing soon.
$ReNew Energy Global (RNW.US)$ - unconventional and renewable energy company in India.
$Vivid Seats (SEAT.US)$ - Online marketplace for event tickets. Good competition vs. $Live Nation Entertainment (LYV.US)$
$Array Technologies (ARRY.US)$ Tracking equipment and software for solar panels, allowing them to increase efficiency following the sun through the day.
$Invivyd (IVVD.US)$ - makes COVID antibodies, w/ a phase 3 trial completing soon.
$ReNew Energy Global (RNW.US)$ - unconventional and renewable energy company in India.
$Vivid Seats (SEAT.US)$ - Online marketplace for event tickets. Good competition vs. $Live Nation Entertainment (LYV.US)$
$Array Technologies (ARRY.US)$ Tracking equipment and software for solar panels, allowing them to increase efficiency following the sun through the day.
3
1
$Invivyd (IVVD.US)$
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
Invivyd (Nasdaq: IVVD) announced that the FDA has updated the Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) with accurate SARS-CoV-2 variant susceptibility data. The updated Fact Sheet, dated September 26, 2024, includes in vitro neutralization activity against dominant circulating variants, including KP.3....
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
Invivyd (Nasdaq: IVVD) announced that the FDA has updated the Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) with accurate SARS-CoV-2 variant susceptibility data. The updated Fact Sheet, dated September 26, 2024, includes in vitro neutralization activity against dominant circulating variants, including KP.3....
$Invivyd (IVVD.US)$ Reuters
Just
Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data
Just
Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data
No comment yet
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...